Phase I results from the phase I/II study of Rezlidhia (olutasidenib), an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1, suggests that Rezlidhia, with or without azacitidine, was well-tolerated and was associated with improvements in clinical efficacy endpoints in patients with mIDH1 acute myeloid leukemia.
Marina Konopleva, director of the Leukemia Program and co-director of the Blood Cancer Institute at the Montefiore Einstein Comprehensive Cancer Center, has joined Break Through Cancer, a collaborative medical research foundation that supports teams of scientists as they advance treatments for some of the world’s deadliest cancers.
